Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.41 |
| ▸ | GIPR | P48546 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | DDHD2 | O94830 | 1/20 | 0.38 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.36 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718416 | 0.84 | GCGR (0.46) | GCGRGIPRFAAHDDHD2DAGLB | |
| SCHEMBL3403205 | 0.83 | FAAH (0.43) | GCGRFAAHDAGLAKDM4E | |
| SCHEMBL718909 | 0.72 | GCGR (0.41) | GCGRGIPRFAAHDDHD2DAGLB | |
| SCHEMBL718313 | 0.70 | MEN1 (0.43) | FAAH | |
| SCHEMBL4683632 | 0.68 | GCGR (0.49) | GCGRGIPRFAAHPOLB | |
| SCHEMBL21484760 | 0.67 | KDM4E (0.47) | KDM4EALDH1A1POLBCTSLCTSS | |
| SCHEMBL719209 | 0.67 | GCGR (0.59) | GCGRGIPRFAAH | |
| SCHEMBL2250241 | 0.65 | GCGR (0.72) | GCGRGIPR | |
| SCHEMBL716806 | 0.65 | GCGR (0.43) | GCGRKDM4E | |
| SCHEMBL718990 | 0.65 | FAAH (0.59) | GCGRFAAHKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GIPR 41/4885FAAH 4513/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCGR 90/4885GIPR 41/4885FAAH 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.